创伤性出血试验样本量方法学的系统评价与Meta分析
该系统评价纳入13项评估改善成人创伤性出血生存干预措施的RCT,比较样本量估算中的估计值与实际结局数据。结果发现11/13项试验为阴性,所有研究均未准确估计死亡率,除1项外均高估死亡率降低幅度(中位绝对死亡率降低3% vs 目标10%),仅CRASH-2使用最小临床重要差异设定治疗效应目标,无研究采用预后富集;8/13项研究被终止,主要因无效。作者认为当前试验方法学受限于不精确的对照组风险估计、过于乐观的治疗效应估计及缺乏透明论证,推荐未来创伤RCT纳入预后富集、基于临床重要性和现实可行性论证目标治疗差异,并透明报告假设。
要点
- 13项创伤出血RCT中11项为阴性,8项被终止,主要因无效。
- 所有研究均未准确估计死亡率,除1项外均高估死亡率降低幅度。
- 中位绝对死亡率降低为3%,而目标为10%。
- 仅CRASH-2使用最小临床重要差异设定治疗效应目标,无研究采用预后富集。
- 作者建议未来创伤RCT纳入预后富集、合理论证目标差异并透明报告假设。
适用人群与场景
- 成人创伤相关出血患者,评估旨在改善生存的干预措施的RCT。
- 多数研究为多中心、在北美开展,纳入钝性和穿透性损伤患者。
诊断标准与关键阈值
- 各研究对失血性休克的定义标准不一。
研究设计与关键结果
- 系统评价纳入13项RCT,其中11项为阴性结果。
- 所有研究均未在样本量计算中准确估计死亡率。
- 除1项研究外,其余研究均高估样本量计算中的死亡率降低幅度;中位绝对死亡率降低为3%,而目标为10%。
- 仅CRASH-2研究使用最小临床重要差异设定治疗效应目标。
- 无RCT采用预后富集。
- 8/13项研究被终止,主要因无效。
证据类型、等级与局限
- 证据类型:系统评价/Meta分析;证据等级:Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议未来开展创伤RCT时纳入预后富集以 informing 基线风险,基于临床重要性和现实可行性论证目标治疗差异,并对所作假设保持透明并提供依据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma hemorrhage remains the most common cause of preventable mortality in trauma. To guide clinical practice, RCTs provide high-quality evidence to inform clinical decision making. The clinical relevance and inferences made by RCTs are dependent on assumptions made during sample size calculation.
METHODS: To describe the quality of methodology for sample size determination, we conducted a systemic review RCTs evaluating interventions that aim to improve survival in adults with trauma-related hemorrhage. Estimated and actual outcome data are compared, including components of sample size determination.
RESULTS: A total of 13 RCTs were included. We noted a high rate of negative trial results (11 of 13 studies). Most studies were multi-center and conducted in North America, evaluating patients with blunt and penetrating injuries. The criteria for hemorrhagic shock varied across studies. All studies did not accurately estimate the mortality rate during sample size calculation. All but one study overestimated the mortality reduction during sample size calculation; the median absolute mortality reduction was 3%, compared with a target of 10%. Only the CRASH-2 study used a minimal clinically important different for treatment effect target. No RCTs employed prognostic enrichment. Most studies were terminated (8 of 13), mainly for futility.
CONCLUSION: Taken together, this review highlights that current clinical trial methodology is limited by imprecise control group risk estimates, overly optimistic treatment effect estimates, and lack of transparent justification for such targets. These limitations result in studies at high risk for futility and potentially premature abandonment of promising therapies. Given the high morbidity and mortality of trauma-related hemorrhage, we recommend that future conduct of trauma RCTs incorporate (1) prognostic enrichment to inform baseline risk, (2) justify target treatment differences based on clinical importance and realistic estimates of feasibility, and (3) be transparent and provide justification for the assumptions made.
LEVEL OF EVIDENCE: Systematic Review/Meta-Analysis; Level III.
参考来源
- Ghossein J, Fernando SM, Rochwerg B, et al. A systematic review and meta-analysis of sample size methodology for traumatic hemorrhage trials. J Trauma Acute Care Surg. 2023. PMID: 36879398. doi:10.1097/TA.0000000000003944
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。